Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective

References

• Ferreira JJ, Katzenschlager R, Bloem BR, et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol. 2013;20(1):5–15.
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–1683.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14(7):675–684.
   PubMed Web of Science ®Google Scholar
• Schapira AH, Agid Y, Barone P, et al. Perspectives on recent advances in the understanding and treatment of Parkinson’s disease. Eur J Neurol. 2009;16(10):1090–1099.
   PubMed Web of Science ®Google Scholar
• Olanow W, Schapira AH, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson’s disease. Trends Neurosci. 2000;23(10 Suppl):S117–126.
   PubMed Web of Science ®Google Scholar
• Calon F, Hadj Tahar A, Blanchet PJ, et al. Dopamine-receptor stimulation: biobehavioral and biochemical consequences. Trends Neurosci. 2000;23(10 Suppl):S92–100.
   PubMed Web of Science ®Google Scholar
• Gershanik O, Jenner P. Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson’s disease. Eur J Neurol. 2012;19(12):1502–1508.
   PubMed Web of Science ®Google Scholar
• Hisahara S, Shimohama S. Dopamine receptors and Parkinson’s disease. Int J Med Chem. 2011;2011:403039.
   PubMedGoogle Scholar
• Reichmann H, Odin P, Brecht HM, et al. Changing dopamine agonist treatment in Parkinson’s disease: experiences with switching to pramipexole. J Neural Transm Suppl. 2006;71:17–25.
   PubMedGoogle Scholar
• Oertel WH, Berardelli A, Bloem BR, Bonuccelli U, et al. Early (uncomplicated) Parkinson’s disease. In: Gilhus NE, Barnes MP, Brainin M, Eds. European Handbook of Neurological Management. Oxford, UK: Blackwell Publishing Ltd.; 2011. p. 217–236.
   Google Scholar
• Junghanns S, Glockler T, Reichmann H. Switching and combining of dopamine agonists. J Neurol. 2004;251(Suppl 6):VI/19–23.
   PubMedGoogle Scholar
• Reichmann H, Herting B, Miller A, et al. Switching and combining dopamine agonists. J Neural Transm (Vienna). 2003;110(12):1393–1400.
   PubMed Web of Science ®Google Scholar
• Thobois S. Proposed dose equivalence for rapid switch between dopamine receptor agonists in Parkinson’s disease: a review of the literature. Clin Ther. 2006;28(1):1–12.
   PubMed Web of Science ®Google Scholar
• Sieb JP, Themann P, Warnecke T, et al. Caregivers’ and physicians’ attitudes to rotigotine transdermal patch versus oral Parkinson’s disease medication: an observational study. Curr Med Res Opin. 2015;31(5):967–974.
   PubMed Web of Science ®Google Scholar
• Wüllner U, Fuchs G, Reketat N, et al. Requirements for Parkinson’s disease pharmacotherapy from the patients’ perspective: a questionnaire-based survey. Curr Med Res Opin. 2012;28(7):1239–1246.
   PubMed Web of Science ®Google Scholar
• Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol. 2009;379(1):73–86.
   PubMed Web of Science ®Google Scholar
• Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther. 2012;34(4):966–978.
   PubMed Web of Science ®Google Scholar
• UCB. US prescribing information Neupro. 2015. [cited 2016 Jul 25], Available at http://www.ucb.com/_up/ucb_com_products/documents/Neupro_Current_COL_02-2015.pdf.
   Google Scholar
• European Medicines Agency. Summary of products characteristics - Neupro. 2016. [cited 2016 Jul 25], Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000626/WC500026397.pdf.
   Google Scholar
• Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol. 2003;60(12):1721–1728.
   PubMedGoogle Scholar
• Jankovic J, Watts RL, Martin W, Group SPRTSCS. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol. 2007;64(5):676–682.
   PubMed Web of Science ®Google Scholar
• Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology. 2007;68(4):272–276.
   PubMed Web of Science ®Google Scholar
• Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord. 2007;22(16):2398–2404.
   PubMed Web of Science ®Google Scholar
• Zhang ZX, Shang HF, Hu X, et al. Rotigotine transdermal patch in Chinese patients with early Parkinson’s disease: a randomized, double-blind, placebo-controlled pivotal study. Parkinsonism Relat Disord. 2016;28:49–55.
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Nomoto M, Kondo T, et al. Transdermal rotigotine in early stage Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. Mov Disord. 2013;28(10):1447–1450.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Lyons KE, Pahwa R. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007;68(16):1262–1267.
   PubMed Web of Science ®Google Scholar
• Nicholas AP, Borgohain R, Chana P, et al. A randomized study of rotigotine dose response on ‘off’ time in advanced Parkinson’s disease. J Parkinsons Dis. 2014;4(3):361–373.
   PubMedGoogle Scholar
• Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007;6(6):513–520.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Asgharnejad M, Xue H, et al. Chinese patients with advanced Parkinson’s disease: a randomized, double-blind study [abstract]. Mov Disord. 2016;31:suppl 2.
   Google Scholar
• Nomoto M, Mizuno Y, Kondo T, et al. Transdermal rotigotine in advanced Parkinson’s disease: a randomized, double-blind, placebo-controlled trial. J Neurol. 2014;261(10):1887–1893.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Kies B, Rudzinska M, et al. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26(1):90–99.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Benes H, Poewe W, et al. Efficacy of rotigotine for treatment of moderate-to-severe restless legs syndrome: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2008;7(7):595–604.
   PubMed Web of Science ®Google Scholar
• Hening WA, Allen RP, Ondo WG, et al. Rotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United States. Mov Disord. 2010;25(11):1675–1683.
   PubMed Web of Science ®Google Scholar
• Oertel WH, Benes H, Garcia-Borreguero D, et al. Rotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic study. Sleep Med. 2010;11(9):848–856.
   PubMed Web of Science ®Google Scholar
• Sujith OK, Lane C. Therapeutic options for continuous dopaminergic stimulation in Parkinson’s disease. Ther Adv Neurol Disord. 2009;2(2):105–113.
   PubMedGoogle Scholar
• Kim J-S, Sung H-Y. Gastrointestinal autonomic dysfunction in patients with Parkinson’s disease. J Mov Disord. 2015;8(2):76–82.
   PubMedGoogle Scholar
• Seppi K, Weintraub D, Coelho M, et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord. 2011;26(Suppl 3):S42–S80.
   PubMed Web of Science ®Google Scholar
• Woitalla D, Kassubek J, Timmermann L, et al. Reduction of gastrointestinal symptoms in Parkinson’s disease after a switch from oral therapy to rotigotine transdermal patch: a non-interventional prospective multicenter trial. Parkinsonism Relat Disord. 2015;21(3):199–204.
   PubMed Web of Science ®Google Scholar
• Mukherjee A, Biswas A, Das SK. Gut dysfunction in Parkinson’s disease. World J Gastroenterol. 2016;22(25):5742–5752.
   PubMed Web of Science ®Google Scholar
• Wüllner U, Kassubek J, Odin P, et al. Transdermal rotigotine for the perioperative management of Parkinson’s disease. J Neural Transm. 2010;117(7):855–859.
   PubMed Web of Science ®Google Scholar
• Högl B, Oertel WH, Schollmayer E, et al. Transdermal rotigotine for the perioperative management of restless legs syndrome. BMC Neurol. 2012;12(1):106.
   PubMed Web of Science ®Google Scholar
• Weintraub D, David AS, Evans AH, et al. Clinical spectrum of impulse control disorders in Parkinson’s disease. Mov Disord. 2015;30(2):121–127.
   PubMed Web of Science ®Google Scholar
• Mestre TA, Strafella AP, Thomsen T, et al. Diagnosis and treatment of impulse control disorders in patients with movement disorders. Ther Adv Neurol Disord. 2013;6(3):175–188.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–595.
   PubMed Web of Science ®Google Scholar
• Weintraub D, Siderowf AD, Potenza MN, et al. Dopamine agonist use is associated with impulse control disorders in Parkinson’s disease. Arch Neurol. 2006;63(7):969–973.
   PubMedGoogle Scholar
• Perez-Lloret S, Rey MV, Fabre N, et al. Prevalence and pharmacological factors associated with impulse-control disorder symptoms in patients with Parkinson disease. Clin Neuropharmacol. 2012;35(6):261–265.
   PubMed Web of Science ®Google Scholar
• Garcia-Ruiz PJ, Martinez Castrillo JC, Alonso-Canovas A, et al. Impulse control disorder in patients with Parkinson’s disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840–844.
   PubMed Web of Science ®Google Scholar
• Rizos A, Sauerbier A, Antonini A, et al. A European multicentre survey of impulse control behaviours in Parkinson’s disease patients treated with short- and long-acting dopamine agonists. Eur J Neurol. 2016;23(8):1255–1261.
   PubMed Web of Science ®Google Scholar
• Seeman P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69(4):183–189.
   PubMed Web of Science ®Google Scholar
• Antonini A, Chaudhuri KR, Boroojerdi B, et al. Impulse control disorder related behaviours during long‐term rotigotine treatment: a post hoc analysis. Eur J Neurol. 2016;23(10):1556–1565.
   PubMed Web of Science ®Google Scholar
• Cornelius JR, Tippmann-Peikert M, Slocumb NL, et al. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep. 2010;33(1):81–87.
   PubMed Web of Science ®Google Scholar
• Schreglmann SR, Gantenbein AR, Eisele G, et al. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord. 2012;18(2):207–209.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Hogl B, Ferini-Strambi L, et al. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks. Mov Disord. 2012;27(2):277–283.
   PubMed Web of Science ®Google Scholar
• Oertel W, Trenkwalder C, Benes H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol. 2011;10(8):710–720.
   PubMed Web of Science ®Google Scholar
• Godau J, Berg D. Rotigotine in the long-term treatment of severe RLS with augmentation: a series of 28 cases. Sleep Disord. 2011;2011:468952.
   PubMedGoogle Scholar
• Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11.
   PubMed Web of Science ®Google Scholar
• Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson’s disease: is rapid titration preferable to slow? Neurology. 1999;52(6):1227–1229.
   PubMed Web of Science ®Google Scholar
• Canesi M, Antonini A, Mariani CB, et al. An overnight switch to ropinirole therapy in patients with Parkinson’s disease. Short communication. J Neural Transm (Vienna). 1999;106(9–10):925–929.
   PubMed Web of Science ®Google Scholar
• LeWitt PA, Boroojerdi B, MacMahon D, et al. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol. 2007;30(5):256–265.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Jeon BS, Lee WY, et al. Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease. BMC Neurol. 2011;11:100.
   PubMed Web of Science ®Google Scholar
• Chung SJ, Kim JM, Kim JW, et al. Switch from oral pramipexole or ropinirole to rotigotine transdermal system in advanced Parkinson’s disease: an open-label study. Expert Opin Pharmacother. 2015;16(7):961–970.
   PubMed Web of Science ®Google Scholar
• Reid J. Acute management of Parkinson’s patients. 2011. [cited 2016 Jul 18], Available at https://pennorth.files.wordpress.com/2015/02/fifeacute-management-of-parkinsons-patients.pdf.
   Google Scholar
• Tomlinson CL, Stowe R, Patel S, et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–2653.
   PubMed Web of Science ®Google Scholar
• Brennan KA, Genever RW. Managing Parkinson’s disease during surgery. BMJ. 2010;341:c5718.
   PubMed Web of Science ®Google Scholar
• Leitlinien für Diagnostik und Therapie in der Neurologie. Idiopathisches Parkinson-Syndrom. 2016. [cited 2016 Sep 19], Available at http://www.dgn.org/images/red_leitlinien/LL_2016/PDFs_Download/030010_LL_langfassung_ips_2016.pdf.
   Google Scholar
• Elshoff JP, Timmermann L, Schmid M, et al. Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations. Curr Med Res Opin. 2013;29(12):1657–1662.
   PubMed Web of Science ®Google Scholar
• Chitnis S, Jaffery M, Dewey RB. Outcomes from switching from rotigotine patch to alternate therapies in Parkinson’s disease. Int J Neurosci. 2012;122(1):22–25.
   PubMed Web of Science ®Google Scholar
• Winkelman JW, Mackie SE, Mei LA, et al. A method to switch from oral dopamine agonists to rotigotine in patients with restless legs syndrome and mild augmentation. Sleep Med. 2016;24:18–23.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Canelo M, Lang M, et al. Management of augmentation of restless legs syndrome with rotigotine: a 1-year observational study. Sleep Med. 2017;30:257-265.
   Web of Science ®Google Scholar
• Stiasny-Kolster K, Berg D, Hofmann WE, et al. Effectiveness and tolerability of rotigotine transdermal patch for the treatment of restless legs syndrome in a routine clinical practice setting in Germany. Sleep Med. 2013;14(6):475–481.
   PubMed Web of Science ®Google Scholar